Immuneering Corporation - Class A Common Stock (NQ:IMRX)

5.200 +0.100 (+1.96%)

Streaming Delayed Price Updated: 12:33 PM EST, Feb 25, 2026 Add to My Watchlist

Price and Volume

Volume	179,656
Open	5.100
Bid (Size)	5.190 (500)
Ask (Size)	5.220 (1,000)
Prev. Close	5.100
Today's Range	5.100 - 5.280
52wk Range	1.100 - 10.08
Shares Outstanding	25,938,064
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026

From Immuneering Corporation

Via GlobeNewswire

Here are the top movers in Thursday's session. ↗

January 08, 2026

Via Chartmill

Performance

YTD	-21.5%	-21.5%
1 Month	-0.4%	-0.4%
3 Month	-30.1%	-30.1%
6 Month	-12.2%	-12.2%
1 Year	+207.7%	+207.7%

More News

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

January 08, 2026

Via Chartmill

IMRX Stock Closed Over 20% Higher Today: Here’s Why ↗

January 07, 2026

Via Stocktwits

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Why Immuneering Stock Soared Over 40% After-Hours Today ↗

September 24, 2025

Via Stocktwits

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 07, 2026

Via Chartmill

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

January 07, 2026

From Immuneering Corporation

Via GlobeNewswire

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

December 23, 2025

From Immuneering Corporation

Via GlobeNewswire

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

December 17, 2025

From Immuneering Corporation

Via GlobeNewswire

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

December 16, 2025

From Immuneering Corporation

Via GlobeNewswire

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

From Immuneering Corporation

Via GlobeNewswire

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

November 19, 2025

Via FinancialNewsMedia

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

November 19, 2025

From FN Media Group LLC

Via GlobeNewswire

Immuneering (IMRX) Q3 2025 Earnings Transcript ↗

November 13, 2025

Via The Motley Fool

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

November 12, 2025

From Immuneering Corporation

Via GlobeNewswire

A Preview Of Immuneering's Earnings ↗

November 11, 2025

Via Benzinga

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

November 04, 2025

From Immuneering Corporation

Via GlobeNewswire

Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data

September 27, 2025

Via MarketMinute

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

September 26, 2025

From Immuneering Corporation

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 25, 2025

Via Benzinga

Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket ↗

September 25, 2025

Via Benzinga

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

September 25, 2025

From Immuneering Corporation

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 24, 2025

Via Benzinga

Frequently Asked Questions

Is Immuneering Corporation - Class A Common Stock publicly traded?

Yes, Immuneering Corporation - Class A Common Stock is publicly traded.

What exchange does Immuneering Corporation - Class A Common Stock trade on?

Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Immuneering Corporation - Class A Common Stock?

The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market

What is the current price of Immuneering Corporation - Class A Common Stock?

The current price of Immuneering Corporation - Class A Common Stock is 5.200

When was Immuneering Corporation - Class A Common Stock last traded?

The last trade of Immuneering Corporation - Class A Common Stock was at 02/25/26 12:33 PM ET

What is the market capitalization of Immuneering Corporation - Class A Common Stock?

The market capitalization of Immuneering Corporation - Class A Common Stock is 134.88M

How many shares of Immuneering Corporation - Class A Common Stock are outstanding?

Immuneering Corporation - Class A Common Stock has 135M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.